MoonLake Immunotherapeutics (MLTX) Insider Trading Activity

NASDAQ$15.01
Market Cap
$1.26B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
308 of 853
Rank in Industry
174 of 492

MLTX Insider Trading Activity

MLTX Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$98,808
1
4
Sells
$129,894,803
27
96

Related Transactions

Bodenstedt MatthiasChief Financial Officer
1
$98,808
7
$3.2M
$-3.1M
Reich KristianChief Scientific Officer
0
$0
10
$8.14M
$-8.14M
Santos da Silva JorgeChief Executive Officer
0
$0
7
$8.73M
$-8.73M
Chen BihuaFormer 10% Owner
0
$0
2
$46.87M
$-46.87M
BVF PARTNERS L P/IL
0
$0
1
$62.96M
$-62.96M

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.

Insider Activity of MoonLake Immunotherapeutics

Over the last 12 months, insiders at MoonLake Immunotherapeutics have bought $98,808 and sold $129.89M worth of MoonLake Immunotherapeutics stock.

On average, over the past 5 years, insiders at MoonLake Immunotherapeutics have bought $27.36M and sold $89.32M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Bodenstedt Matthias (Chief Financial Officer) — $98,808.

The last purchase of 10,870 shares for transaction amount of $98,808 was made by Bodenstedt Matthias (Chief Financial Officer) on 2025‑10‑08.

List of Insider Buy and Sell Transactions, MoonLake Immunotherapeutics

2026-07-27SaleReich KristianChief Scientific Officer
1,100
0.0013%
$20.00
$22,000
-17.15%
2026-07-22SaleReich KristianChief Scientific Officer
2,448
0.0031%
$20.00
$48,960
-12.65%
2026-07-21SaleReich KristianChief Scientific Officer
50,000
0.0604%
$20.02
$1M
-17.30%
2026-07-20SaleReich KristianChief Scientific Officer
43,700
0.0558%
$20.09
$877,933
-12.52%
2026-07-15SaleReich KristianChief Scientific Officer
16,105
0.0195%
$20.01
$322,261
-13.68%
2026-07-10SaleSantos da Silva JorgeChief Executive Officer
68,289
0.0912%
$20.02
$1.37M
-14.71%
2026-07-09SaleSantos da Silva JorgeChief Executive Officer
33,936
0.0463%
$20.01
$679,059
-12.69%
2026-07-01SaleSantos da Silva JorgeChief Executive Officer
47,775
0.068%
$20.03
$956,933
-6.01%
2026-06-22SaleBodenstedt MatthiasChief Financial Officer
39,120
0.0529%
$22.04
$862,205
-16.79%
2026-06-18SaleBodenstedt MatthiasChief Financial Officer
2,794
0.0039%
$19.60
$54,762
-3.31%
2026-06-17SaleReich KristianChief Scientific Officer
50,000
0.0695%
$19.43
$971,500
-2.50%
2026-06-17SaleBodenstedt MatthiasChief Financial Officer
15,082
0.021%
$19.68
$296,814
-2.50%
2026-06-16SaleReich KristianChief Scientific Officer
50,000
0.0669%
$18.70
$935,000
-0.97%
2026-06-15SaleReich KristianChief Scientific Officer
50,000
0.0669%
$18.89
$944,500
-1.62%
2026-05-11SaleBodenstedt MatthiasChief Financial Officer
13,653
0.0199%
$20.02
$273,333
-2.39%
2026-04-14SaleBodenstedt MatthiasChief Financial Officer
2,426
0.0034%
$19.56
$47,453
-4.02%
2026-04-13SaleSantos da Silva JorgeChief Executive Officer
51,873
0.0679%
$18.23
$945,645
-2.17%
2026-04-10SaleSantos da Silva JorgeChief Executive Officer
98,127
0.1298%
$18.41
$1.81M
+0.84%
2026-04-10SaleBodenstedt MatthiasChief Financial Officer
1,925
0.0027%
$19.51
$37,557
+0.84%
2026-04-09SaleBodenstedt MatthiasChief Financial Officer
85,870
0.1328%
$18.94
$1.63M
-7.11%
Total: 56
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Santos da Silva JorgeChief Executive Officer
2774893
3.2989%
$41.65M014
Reich KristianChief Scientific Officer
2711198
3.2232%
$40.7M017
Chen BihuaFormer 10% Owner
1994173
2.3708%
$29.93M82
<0.0001%
Bodenstedt MatthiasChief Financial Officer
1115435
1.3261%
$16.74M19
BVF PARTNERS L P/IL
1039238
1.2355%
$15.6M02
Helix Holdings LLC
430000
0.5112%
$6.45M10
<0.0001%
Sturge Simondirector
171980
0.2045%
$2.58M01
Moukheibir Catherinedirector
0
0%
$001
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$831,902,292
108
9.34%
$1.3B
$100,473,344
83
9.53%
$1.21B
$15,410,062
81
39.69%
$1.1B
$276,808,393
17
-6.69%
$1.17B
$11,845,103
12
14.43%
$1.18B
$2,314,489
11
-0.78%
$1.37B
$186,141,911
11
-8.72%
$1.23B
$1,229,070
10
23.53%
$1.37B
$140,543,039
10
0.77%
$1.29B
MoonLake Immunotherapeutics
(MLTX)
$117,959,652
9
-12.47%
$1.26B
$38,624,786
9
1.26%
$1.36B
$49,165,200
7
12.92%
$1.26B
$19,683,752
7
6.05%
$1.33B
$112,382,168
4
-48.89%
$1.36B
$25,999,974
4
0.00%
$1.44B
$704,400
2
-29.92%
$1.07B
$12,750
2
-39.73%
$1.01B
$44,400
1
49.80%
$1.21B
$13,900
1
-39.25%
$1.02B

MLTX Institutional Investors: Active Positions

Increased Positions105+68.63%27M+71.56%
Decreased Positions74-48.37%9M-22.9%
New Positions50New14MNew
Sold Out Positions50Sold Out7MSold Out
Total Postitions184+20.26%56M+48.66%

MLTX Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Bvf Inc/Il$236,028.0027.82%19.75M00%2025-09-30
Avoro Capital Advisors Llc$23,900.002.82%2M-2M-51.81%2025-09-30
Cormorant Asset Management, Lp$23,830.002.81%1.99M-6M-76.52%2025-09-30
Balyasny Asset Management L.P.$20,306.002.39%1.7M+1M+301.55%2025-09-30
Adage Capital Partners Gp, L.L.C.$17,925.002.11%1.5M+2MNew2025-09-30
Schonfeld Strategic Advisors Llc$11,537.001.36%965,405+965,405New2025-09-30
Price T Rowe Associates Inc /Md/$9,834.001.16%822,957-2M-68.51%2025-09-30
Fmr Llc$8,687.001.02%726,932-5M-87.31%2025-09-30
Nuveen, Llc$7,597.000.9%635,699-155,856-19.69%2025-09-30
Two Sigma Investments, Lp$5,429.000.64%454,268+454,268New2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.